Cathie Wood Sells Palantir Shares Worth $2.65 Million Ahead Of Earnings, Doubles Down On This Chip Giant
BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $80
US Health Secretary Reportedly Says 35 States to Join Pilot Program for Sickle Cell Disease Gene Therapies
CRISPR Therapeutics AG (NASDAQ:CRSP) Is Largely Controlled by Institutional Shareholders Who Own 73% of the Company
'Incoming Regulatory Tailwinds' to Spur 90% Upside for CRISPR Therapeutics Stock, Says BMO Capital
BMO Capital Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $97
